Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study
about
Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studiesEmerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptinAlogliptin benzoate for management of type 2 diabetesCardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension studyEfficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinidesComparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonClinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Analyzing the Factors Contributing to Withdrawal from Insulin Therapy Following Additional Administration of Alogliptin: Retrospective Study after Removing Glucotoxicity with Insulin.Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot studyPathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.Alogliptin benzoate for the treatment of type 2 diabetes.Efficacy of voglibose in type 2 diabetes.Alogliptin: a review of its use in patients with type 2 diabetes mellitus.Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.Meta-analysis and critical review on the efficacy and safety of alpha glucosidase inhibitors in Asian and non-Asian populations.Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan.Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis.Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors.Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis.Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study
P2860
Q24288949-1DB82D26-22DF-4D07-A74B-AEFF59481A33Q27008952-D303B69D-84B4-4E01-AE51-C7BB48ED3163Q28083933-52A362D4-2C76-4C1F-BD69-1F41ED2D4620Q30240823-EA20EE60-6AFA-4E6E-AA53-CBFA1E05E5A9Q30241808-E08ABC19-C72B-4AEE-91F7-0C006C79766EQ33587818-8BBA8615-78FB-426D-A83D-06016ECA721CQ33622260-A47F3B3B-9192-4692-95F7-A04475ED9D9BQ33785197-022422E4-6C1F-4105-A14C-7EF3EC4BA7DAQ35236019-510E4A62-E792-44AE-8A77-6B853B1CA5FEQ36082398-C096DCCA-1E63-4F54-9EB7-68F0925750B9Q36315963-538E74C6-98D8-463A-A9BD-FA7DB2DAB125Q36701703-3CBB6FAE-D5AE-41D5-8A68-6AD1241FBCE7Q37195882-98BBCB06-DBB3-4083-82BB-5869F1050A93Q37394740-A7C356D7-9501-4C2D-AE9C-1F2E690CE8D7Q37446672-1A0BD0E9-255E-443A-A8A3-074B5CF8D3A5Q38076330-8492C9D6-7823-40E4-8F4E-85CF6B1F371BQ38197275-70F8B54B-6C01-42A6-AC87-A78D01958EB3Q38209518-F002DC40-F9F0-4667-86FB-C2958EA0F992Q38412153-1637E50B-F9B3-48F5-9086-3DAD9278A843Q38546981-2AF70E51-64AB-4AF6-B23A-40FBA5DCA852Q38556037-77F594FB-FACD-4FD2-8B3F-065C5BB1B2F1Q38647717-7E4AE07D-BDAB-4926-A18E-A7801A457D57Q38716033-056C02D0-B396-4594-9BB7-6B16C5075563Q38778476-8F817BF8-77F2-4068-9B6C-6FFD8ABC3115Q38795046-E58B7FB9-662D-4F77-8776-E8D1614CA043Q39420555-A8386C36-B40A-4DE0-A05F-0F6351C5B352Q40757945-981593E3-5422-4FDC-9ED0-C9433A5750B7Q42149446-DA84C520-3E1C-4313-92B2-1F31E1CC8B3AQ42695369-E396D0D2-9332-4DAF-ACEC-442B3136EA7FQ42876103-320D17A2-0651-4424-943B-07FE161D778BQ43462577-8963B019-11D1-4707-B4FF-A161DE9BE046Q43853440-DC147D87-ED94-4726-B0A1-CA12A5639F42Q45772366-A9D241CC-05D3-4085-90D4-8760F45A1406Q47674613-34EB3569-86E6-4465-AFE5-204D8B460D07Q51301791-3B6E4A02-4D2E-4FE8-95FB-CD912081A607Q57591345-3C701DCE-B4BF-4992-8779-50342F0D24CF
P2860
Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Efficacy and safety of aloglip ...... by a long-term extension study
@ast
Efficacy and safety of aloglip ...... by a long-term extension study
@en
Efficacy and safety of aloglip ...... by a long-term extension study
@nl
type
label
Efficacy and safety of aloglip ...... by a long-term extension study
@ast
Efficacy and safety of aloglip ...... by a long-term extension study
@en
Efficacy and safety of aloglip ...... by a long-term extension study
@nl
prefLabel
Efficacy and safety of aloglip ...... by a long-term extension study
@ast
Efficacy and safety of aloglip ...... by a long-term extension study
@en
Efficacy and safety of aloglip ...... by a long-term extension study
@nl
P2093
P921
P3181
P1476
Efficacy and safety of aloglip ...... by a long-term extension study
@en
P2093
Kohei Kaku
Masashi Hirayama
Shinzo Hiroi
Tetsuya Fujita
Yutaka Seino
P304
P3181
P356
10.1185/03007995.2011.599371
P407
P577
2011-09-01T00:00:00Z